Upon completion of the transaction, the combined company will serve approximately 1.6 million students across 176 campuses, including around 38,000 medical students, with the ambition of leading through quality and innovation.
Company closes the first half with 7% growth in adjusted EBITDA (ex-DIS), record student intake at IDOMED and the announcement of the seventh unit of Ibmec’s. Since 2024, R$780 million has been returned to shareholders through dividends and share buybacks.
YDUQS Participações S.A. announces its earnings release schedule for the second quarter of 2026.
FCFE reached R$276 million in the first quarter, a record for the period. Premium brands, Ibmec and IDOMED, now account for 49% of the group’s EBITDA. The acquisition of Unifametro was completed during the quarter.
Free Cash Flow exceeds R$1 billion for the first time. The Premium segment already represents for 44% of EBITDA.